# Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH

> **NCT01092585** · PHASE2 · UNKNOWN · sponsor: **Genta Incorporated** · enrollment: 27 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Tesetaxel

## Key facts

- **NCT ID:** NCT01092585
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-02
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2011-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01092585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01092585, "Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01092585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*